Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients

Fundamental and Clinical Pharmacology

Volumn 25, Issue 5, 2011, Pages 642-651

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Ferrari, Ilaria ^a   D'Angelo, Angela ^a   Fogari, Elena ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Inflammation; l carnitine; Orlistat; TNF ; Type 2 diabetes; Vaspin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADIPONECTIN; C REACTIVE PROTEIN; CARNITINE; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASPIN; VILDAGLIPTIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; DEFECATION; DEFECATION URGENCY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT CHANGE;

ADIPONECTIN; ANTI-INFLAMMATORY AGENTS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CARNITINE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; LACTONES; LEPTIN; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OBESITY; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 80052877985     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00888.x     Document Type: Article

References (49)

1. Fried M., Hainer V., Basdevant A. et al. Interdisciplinary European guidelines on surgery for severe obesity. Rozhl. Chir. (2008) 87 468-476.
2. Pagotto U., Vanuzzo D., Vicennati V., Pasquali R.G. Pharmacological therapy of obesity. G. Ital. Cardiol. (2008) 9 83S-93S.
3. Marović D. Elevated body mass index fatty liver. Srp. Arh. Celok. Lek. (2008) 136 122-125.
4. Lavie C.J., Artham S.M., Milani R.V., Ventura H.O. The obesity paradox: impact of obesity on the prevalence prognosis of cardiovascular diseases. Postgrad. Med. (2008) 120 34-41.
5. Leung W.Y., Thomas G.N., Chan J.C., Tomlinson B. Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin. Ther. (2003) 25 58-80.
6. Zhi J., Melia A.T., Guerciolini R. et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin. Pharmacol. Ther. (1994) 56 82-85.
7. Torgerson J.S., Hauptman J., Boldrin M.N., Sjostrom L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of Type 2 diabetes in obese patients. Diabetes Care (2004) 27 155-161.
8. Uziel G., Garavaglia B., Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve (1988) 11 720-724.
9. Amat di San Filippo C., Taylor M.R., Mestroni L., Botto L.D., Longo N. Cardiomyopathy carnitine deficiency. Mol. Genet. Metab. (2008) 94 162-166.
10. Newsholme E.A., Leech A.R. Biochemistry for medical sciences. John Wiley and Sons, Chichester, 1983, pp. 318-321.
11. Derosa G., Cicero A.F.G., Gaddi A., Mugellini A., Ciccarelli L., Fogari R. The effect of l-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin. Ther. (2003) 25 1429-1439.
12. Rydén L., Standl E., Bartnik M. et al. Guidelines on diabetes, pre-diabetes, cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. (2007) 28 88-136.
13. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. WHO, Geneva, 1997.
14. Lichtenstein A.H., Appel L.J., Brands M. et al. Summary of American heart association diet and lifestyle recommendations revision 2006. Arterioscler. Thromb. Vasc. Biol. (2006) 26 2186-2191.
15. Bunn H.F., Gabbay K.H., Gallop P.M. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science (1978) 200 21-27.
16. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet. Med. (1999) 16 716-730.
17. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia (1972) 8 260-266.
18. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia (1985) 28 412-419.
19. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care (2004) 27 1487-1495.
20. Klose S., Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II). J. Clin. Chem. Clin. Biochem. (1978) 15 121-130.
21. Wahlefeld A.W. Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis, 2nd English edn, Academic Press, Inc, New York, USA, 1974, pp. 18-31.
22. Havel R.J., Edr H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. (1955) 34 1345-1353.
23. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin. Chem. (1972) 18 499-502.
24. Misra A., Garg A. Leptin: its receptor and obesity. J. Investig. Med. (1996) 44 540-548.
25. Zhang M., Tracey K. The cytokine handbook, 3rd edn, Academic Press, San Diego, USA, 1988.
26. Yamauchi T., Kamon J., Waki H. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. (2001) 7 941-946.
27. Hida K., Wada J., Eguchi J. et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. USA (2005) 102 10610-10615.
28. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. (1999) 45 2136-2141.
29. Winer B.J. Statistical principles in experimental design, 2nd edn, McGraw-Hill, New York, USA, 1971.
30. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J. Hypertens. (2009) 27 2121-2158.
31. Gotto A.M. Jr., Amarenco P., Assman G. et al. The ILIB lipid handbook for clinical practice: dyslipidemia and coronary heart disease. 3rd edn, International Lipid Information Bureau, New York, USA, 2003, pp. 1-242.
32. Derosa G., Mugellini A., Ciccarelli L., Fogari R. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin. Ther. (2003) 25 1107-1122.
33. Derosa G., Cicero A.F., Murdolo G. et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes. Metab. (2005) 7 47-55.
34. Derosa G., Cicero A.F., Murdolo G., Ciccarelli L., Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Diabetes Nutr. Metab. (2004) 17 222-229.
35. Derosa G., Maffioli P., Salvadeo S.A. et al. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. Expert Opin. Pharmacother. (2010) 11 1971-1982.
36. Derosa G., Maffioli P., Salvadeo S.A. et al. Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. Metabolism (2010), doi:10.1016/j.metabol.2010.03.010.
37. Sirtori C.R., Calabresi L., Ferrara S. et al. l-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr. Metab. Cardiovasc. Dis. (2000) 10 247-251.
38. Dixon A.N., Valsamakis G., Hanif M.W. et al. Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int. J. Clin. Pract. (2008) 62 1124-1129.
39. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell (2004) 116 337-350.
40. Uysal K.T., Wiesbrock S.M., Marino M.W., Hotamisligil G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature (1997) 389 610-614.
41. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science (1993) 259 87-91.
42. Hotamisligil G.S. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. (1999) 245 621-625.
43. Zwacka T.P., Hornbach V., Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation (2001) 103 1194-1197.
44. Jackson M.B., Ahima R.S. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clin. Sci. (2006) 110 143-152.
45. Berg A.H., Combs T.P., Scherer P.E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. (2002) 13 84-89.
46. Bouskila M., Pajvani U.B., Scherer P.E. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? Int. J. Obes. Relat. Metab. Disord. (2005) 29 S17-S23.
47. Maeda N., Shimomura I., Kishida K. et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. (2002) 8 731-737.
48. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. (2001) 7 947-953.
49. Valsamakis G., McTernan P.G., Chetty R. et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism (2004) 53 430-434.